- Reaction score
- 2,634
I can describe this meeting in ONE word: BRIEF.
I'm really sorry guys, but I could NOT get any questions answered in regards to wounding or even Follica. Dr. Cotsarelis would not comment on any of them, not even trials, status, or anything of the sort. All he could say is that the trials are going. This is really unfortunate because the vast majority, or essentially, almost all of my questions were about wounding or Follica related! Also, I only got a few minutes to talk to him as he was always busy, I tried approaching him two other times before and couldn't get a moment with him.
I recommend doing the following;
Finding another doctor/researcher with just as much knowledge on the matter that isn't affiliated Follica and trying to get as much information as we can. I know many of us are going down the wounding method, and I fully support the initiative, so we just need some details like how big/deep the wound needs to be? When do we add the additional agents like lithium chloride, etc or whatever else may be necessary.
HOWEVER!
Through another source I can confirm this:
Follica is fully alive and still undergoing clinical trials. They we're in 'hibernation mode' but that's all that can be said.
Now, in regards to the PGD2 stuff, this is where I was able to get some answers. So I'll go down the list:
1) Solutions like Setipiprant and AM211 (I have a presentation on that as well which I'll post soon) or other PGD2 inhibitors, SHOULD work just as well topically as they would orally if they go systemic. However, I also asked if they didn't go systemic, would they still be effective in blocking PGD2 in the follicles environment and he answered yes.
2) The inhibitors are not dose dependant.
3) PGD2 levels in early vs. late study baldness have NOT been examined as they don't get tissue for late stage baldness.
4) AM211 works similarly to Setipiprant, but are not dose dependant but had some purity issues.
5) He says he'd be shocked if the congress passed the 21st century act.
6) Dosing for setipiprant would depend on the levels in the skin.
That's all guys!
Many thanks to Dr. Cotsarelis as well for speaking with me! This guy's tough to get a hold of, just wish we could know more about Follica and the wounding protocol.a
I'm really sorry guys, but I could NOT get any questions answered in regards to wounding or even Follica. Dr. Cotsarelis would not comment on any of them, not even trials, status, or anything of the sort. All he could say is that the trials are going. This is really unfortunate because the vast majority, or essentially, almost all of my questions were about wounding or Follica related! Also, I only got a few minutes to talk to him as he was always busy, I tried approaching him two other times before and couldn't get a moment with him.
I recommend doing the following;
Finding another doctor/researcher with just as much knowledge on the matter that isn't affiliated Follica and trying to get as much information as we can. I know many of us are going down the wounding method, and I fully support the initiative, so we just need some details like how big/deep the wound needs to be? When do we add the additional agents like lithium chloride, etc or whatever else may be necessary.
HOWEVER!
Through another source I can confirm this:
Follica is fully alive and still undergoing clinical trials. They we're in 'hibernation mode' but that's all that can be said.
Now, in regards to the PGD2 stuff, this is where I was able to get some answers. So I'll go down the list:
1) Solutions like Setipiprant and AM211 (I have a presentation on that as well which I'll post soon) or other PGD2 inhibitors, SHOULD work just as well topically as they would orally if they go systemic. However, I also asked if they didn't go systemic, would they still be effective in blocking PGD2 in the follicles environment and he answered yes.
2) The inhibitors are not dose dependant.
3) PGD2 levels in early vs. late study baldness have NOT been examined as they don't get tissue for late stage baldness.
4) AM211 works similarly to Setipiprant, but are not dose dependant but had some purity issues.
5) He says he'd be shocked if the congress passed the 21st century act.
6) Dosing for setipiprant would depend on the levels in the skin.
That's all guys!
Many thanks to Dr. Cotsarelis as well for speaking with me! This guy's tough to get a hold of, just wish we could know more about Follica and the wounding protocol.a